The battle for dominance in the weight-loss drug market is heating up, and Novo Nordisk's Wegovy is right in the thick of it. But here's where it gets controversial: despite a strong launch, the company's shares took a hit, dropping 2.4% to 307.55 kroner, as highlighted by Deutsche Bank's Emmanuel Papadakis. This dip comes even as Papadakis acknowledges Wegovy's potential to make waves in the obesity market. So, what gives? And this is the part most people miss: the competition is fiercer than ever. Novo Nordisk's plans to boost Wegovy's accessibility by introducing vials are a smart move, but they're not alone in the game. Eli Lilly's 2024 launch of Zepbound, coupled with a price reduction and expanded online availability, has thrown a wrench into the works. Here’s the bold part: could Eli Lilly's aggressive strategy overshadow Wegovy's market dominance? Or will Novo Nordisk's distribution expansion be enough to keep them ahead? The obesity-drug market is no longer a one-horse race, and the stakes are higher than ever. Thought-provoking question: With both companies vying for the top spot, which strategy do you think will win out—price cuts and online accessibility, or expanded distribution methods? Let’s discuss in the comments!
